Precision diagnostics biotech wins newest round of investor backing in bid to facilitate company expansion
Diagnostics firm BillionToOne raised $55 million in a Series B last year in a bid to expand the company, which markets a prenatal screening test. Nine months later, thanks to some more investors, the company officially has more money in its war chest to work with.
The California diagnostics company announced an oversubscribed Series C early this morning, netting $125 million in its largest raise to date. That raise comes from a range of investors, co-led by Adams Street Partners and Hummingbird Ventures. A few other investors include Norwest Venture Partners, Fifty Years VC and Libertus Capital.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
